medullary thyroid carcinoma

From Aaushi
Jump to navigation Jump to search

Introduction

Rare tumor derived from calcitonin-secreting C-cells of the thyroid.

Epidemiology

Pathology

Genetics

Clinical manifestations

Laboratory

* patients with medullary thyroid carcinoma & a pathologic variant RET gene need a rule-out of pheochromocytoma prior to surgery[6]

Radiology

Management

* 131-I is not taken up by C-cells thus not a treatment option for medullary thyroid carcinoma[3]

* MEN-2: medullary thyroid carcinoma, pheochromocytoma, hyperparathyroidism

More general terms

More specific terms

Additional terms

References

  1. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 210, 275
  2. Harrison's Principles of Internal Medicine, 13th ed. Isselbacher et al (eds), McGraw-Hill Inc. NY, 1994, pg 1947
  3. 3.0 3.1 3.2 3.3 3.4 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 15, 16, 17, 18. American College of Physicians, Philadelphia 1998, 2006, 2009, 2012, 2015, 2018.
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  4. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB et al Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009 Jun;19(6):565-612 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19469690
  5. Wells SA Jr, Asa SL, Dralle H et al Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun;25(6):567-610. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/2581004
  6. 6.0 6.1 6.2 NEJM Knowledge+ Endocrinology

Patient information

medullary thyroid carcinoma patient information

Database